CY1107764T1 - Παραγωγη πολυκετιδιων και αλλων φυσικων προϊοντων - Google Patents
Παραγωγη πολυκετιδιων και αλλων φυσικων προϊοντωνInfo
- Publication number
- CY1107764T1 CY1107764T1 CY20071101328T CY071101328T CY1107764T1 CY 1107764 T1 CY1107764 T1 CY 1107764T1 CY 20071101328 T CY20071101328 T CY 20071101328T CY 071101328 T CY071101328 T CY 071101328T CY 1107764 T1 CY1107764 T1 CY 1107764T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- fkbp
- natural products
- analogues
- produce
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229930014626 natural product Natural products 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229930001119 polyketide Natural products 0.000 abstract 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 abstract 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000003881 polyketide derivatives Chemical class 0.000 abstract 1
- 125000000830 polyketide group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0216509A GB0216509D0 (en) | 2002-07-16 | 2002-07-16 | Production of polyketides and other natural products |
| GB0224922A GB0224922D0 (en) | 2002-10-25 | 2002-10-25 | Production of polyketides and other natural products |
| EP05075774A EP1589031B1 (en) | 2002-07-16 | 2003-07-16 | Production of polyketides and other natural products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107764T1 true CY1107764T1 (el) | 2013-04-18 |
Family
ID=30117119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071101328T CY1107764T1 (el) | 2002-07-16 | 2007-10-15 | Παραγωγη πολυκετιδιων και αλλων φυσικων προϊοντων |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7300942B2 (OSRAM) |
| EP (5) | EP1589031B1 (OSRAM) |
| JP (5) | JP2005532809A (OSRAM) |
| CN (1) | CN100569944C (OSRAM) |
| AT (1) | ATE370161T1 (OSRAM) |
| AU (1) | AU2003246965B2 (OSRAM) |
| BR (1) | BR0312691A (OSRAM) |
| CA (1) | CA2492153C (OSRAM) |
| CY (1) | CY1107764T1 (OSRAM) |
| DE (1) | DE60315723T2 (OSRAM) |
| DK (1) | DK1589031T3 (OSRAM) |
| ES (2) | ES2544624T3 (OSRAM) |
| MX (1) | MXPA05000139A (OSRAM) |
| PT (1) | PT1589031E (OSRAM) |
| WO (1) | WO2004007709A2 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1589031E (pt) * | 2002-07-16 | 2007-11-28 | Biotica Tech Ltd | Produção de policétidos e outros produtos naturais |
| CN1882338A (zh) | 2003-09-18 | 2006-12-20 | 马库赛特公司 | 经巩膜递送 |
| MXPA06012404A (es) * | 2004-04-27 | 2007-01-17 | Wyeth Corp | Marcado de rapamicina usando metilasas especificas de rapamicina. |
| MXPA06014080A (es) * | 2004-06-03 | 2007-02-15 | Wyeth Corp | Agregado de genes biosinteticos para la produccion de un policetido complejo. |
| GB0417852D0 (en) * | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
| SG158143A1 (en) | 2004-12-20 | 2010-01-29 | Wyeth Corp | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| CN101084226A (zh) | 2004-12-20 | 2007-12-05 | 惠氏公司 | 雷帕霉素衍生物及其治疗神经紊乱的用途 |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| WO2006086750A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Liquid formulations for treatment of diseases or conditions |
| GB0504995D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| AU2006221774A1 (en) * | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| BRPI0608726A2 (pt) * | 2005-03-11 | 2011-03-15 | Biotica Tech Ltd | uso de um análogo de 39-desmetoxirapamicina ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica |
| CA2635797C (en) | 2006-02-09 | 2015-03-31 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| WO2007112052A2 (en) | 2006-03-23 | 2007-10-04 | Macusight, Inc. | Formulations and methods for vascular permeability-related diseases or conditions |
| GB0609963D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| KR100750810B1 (ko) | 2006-08-07 | 2007-08-22 | 동국제약 주식회사 | 스트렙토마이세스 히그로스코피쿠스 ａｔｃｃ １４８９１변이주 및 이를 이용한 타크로리무스 생산 방법 |
| AU2008234432B2 (en) * | 2007-04-02 | 2014-01-30 | Newsouth Innovations Pty Limited | Methods for producing secondary metabolites |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
| CA2711765A1 (en) * | 2008-01-11 | 2009-07-16 | Massachusetts Eye & Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
| CN102224242B (zh) | 2008-09-24 | 2014-09-24 | 中国科学院上海有机化学研究所 | 新基因簇 |
| GB0904540D0 (en) | 2009-03-17 | 2009-04-29 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0914589D0 (en) | 2009-08-20 | 2009-09-30 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| JP2013544874A (ja) | 2010-12-08 | 2013-12-19 | オスロ ユニヴァーシティー ホスピタル エイチエフ | Ｗｎｔシグナル伝達経路阻害薬としてのトリアゾール誘導体 |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| GB201122305D0 (en) | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
| CN103212064B (zh) * | 2012-01-19 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| KR101331491B1 (ko) | 2012-03-21 | 2013-11-20 | 이화여자대학교 산학협력단 | 증가된 라파마이신 생성능을 갖는 신규 미생물 균주 |
| GB201312318D0 (en) | 2013-07-09 | 2013-08-21 | Isomerase Therapeutics Ltd | Novel methods and compounds |
| WO2017040341A1 (en) * | 2015-08-28 | 2017-03-09 | Buck Institute For Research On Aging | RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY |
| CN110603038A (zh) | 2017-02-10 | 2019-12-20 | 塔姆山治疗公司 | 雷帕霉素类似物 |
| US20210030726A1 (en) * | 2018-02-09 | 2021-02-04 | Torcept Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of neurodegnerative conditions |
| US20210024542A1 (en) * | 2018-02-09 | 2021-01-28 | Torcept Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of cancer |
| CN116947884B (zh) | 2019-01-22 | 2025-10-31 | 艾奥维安制药公司 | Mtorc调节剂及其用途 |
| CN115125179B (zh) * | 2021-03-26 | 2023-10-27 | 上海医药工业研究院 | 产雷帕霉素的基因工程菌及其应用 |
| WO2022272154A2 (en) * | 2021-06-25 | 2022-12-29 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
| US20230104503A1 (en) * | 2021-06-25 | 2023-04-06 | The Regents Of The University Of California | Small molecule compounds |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| SE416705B (sv) | 1978-02-27 | 1981-02-02 | Torsten & Andersson Kaj | Anordning for utskjutning av bollar |
| GB2165090A (en) | 1984-09-26 | 1986-04-03 | Philips Electronic Associated | Improving the field distribution in high voltage semiconductor devices |
| JPS6453991A (en) | 1987-08-25 | 1989-03-01 | Mitsubishi Electric Corp | Magazine-cum-reel |
| US5109112A (en) | 1989-01-19 | 1992-04-28 | Merck & Co., Inc. | FK-506 cytosolic binding protein |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
| WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
| US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5093338A (en) * | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
| WO1992021341A1 (en) | 1991-05-31 | 1992-12-10 | Pfizer Inc. | Use of rapamycin prodrugs as immunosuppressant agents |
| US5763590A (en) | 1991-10-11 | 1998-06-09 | Vertex Pharmaceuticals, Inc. | Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA |
| GB9125660D0 (en) * | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| US5498597A (en) | 1992-01-17 | 1996-03-12 | Dana-Farber Cancer Institute, Inc. | FKBP-13, an FK506-binding immunophilin |
| JP3140228B2 (ja) | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB9302569D0 (en) | 1993-02-10 | 1993-03-24 | Smithkline Beecham Plc | Novel compound |
| US5354845A (en) | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
| GB9315914D0 (en) | 1993-07-31 | 1993-09-15 | Smithkline Beecham Plc | Novel compound |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| UA41884C2 (uk) * | 1993-11-05 | 2001-10-15 | Амерікан Хоум Продактс Корпорейшн | Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів |
| CA2175215C (en) * | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| ATE191218T1 (de) | 1993-12-17 | 2000-04-15 | Novartis Ag | Rapamycin-derivate als immunosuppressoren |
| US5457182A (en) | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| DK0833828T3 (da) | 1995-06-09 | 2003-03-17 | Novartis Ag | Rapamycinderivater |
| ATE286133T1 (de) | 1995-07-06 | 2005-01-15 | Univ Leland Stanford Junior | Zellfreie synthese von polyketiden |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| GB9710962D0 (en) | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
| WO1998001571A2 (en) | 1996-07-05 | 1998-01-15 | Biotica Technology Limited | Erythromycins and process for their preparation |
| PT956034E (pt) | 1996-07-30 | 2002-12-31 | Novartis Ag | Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina |
| AU4246197A (en) * | 1996-09-09 | 1998-03-26 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
| JP2001518784A (ja) * | 1997-04-09 | 2001-10-16 | アイソテクニカ，インコーポレイテッド | ラパマイシンの特異的部位に対する抗体の産生方法 |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| WO1999064040A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
| GB9814006D0 (en) | 1998-06-29 | 1998-08-26 | Biotica Tech Ltd | Polyketides and their synthesis |
| GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
| US6150513A (en) | 1998-09-16 | 2000-11-21 | Kosan Biosciences, Inc. | Polyketide synthase enzymes and recombinant DNA constructs therefor |
| MXPA01003376A (es) * | 1998-10-02 | 2002-11-07 | Kosan Biosciences Inc | Enzimas policetido sintetasa y construcciones de acido desoxirribonucleico recombinante para las mismas. |
| SE516023C2 (sv) | 1999-06-24 | 2001-11-12 | Abb Ab | Industrirobot innefattande en växellådskonfiguration samt förfarande i en industrirobot |
| EP1200078A4 (en) | 1999-07-09 | 2004-06-30 | Univ Oregon Health & Science | COMPOSITIONS AND METHODS ACTIVATING NERVOUS REGENERATION |
| US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
| ATE356880T1 (de) | 1999-10-29 | 2007-04-15 | Kosan Biosciences Inc | Rapamycin analoge |
| CA2405958C (en) | 2000-04-13 | 2011-08-09 | Biotica Technology Limited | Hybrid glycosylated products and their production and use |
| AU6143201A (en) * | 2000-05-17 | 2001-11-26 | Kosan Biosciences Inc | Novel polyketide derivatives |
| GB0019986D0 (en) | 2000-08-14 | 2000-10-04 | Biotica Tech Ltd | Polyketides and their synthesis |
| US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
| GB0128680D0 (en) | 2001-11-29 | 2002-01-23 | Biotica Tech Ltd | Hybrid glycosylated products and their production and use |
| WO2003064383A2 (en) * | 2002-02-01 | 2003-08-07 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
| CA2621517C (en) | 2002-07-16 | 2014-03-25 | Biotica Technology Limited | Production of polyketides fkbp-ligand analogues |
| PT1589031E (pt) | 2002-07-16 | 2007-11-28 | Biotica Tech Ltd | Produção de policétidos e outros produtos naturais |
| AU2007237187B2 (en) | 2002-07-16 | 2010-08-05 | Biotica Technology Limited | Production of polyketides |
| GB0216509D0 (en) | 2002-07-16 | 2002-08-28 | Biotica Tech Ltd | Production of polyketides and other natural products |
-
2003
- 2003-07-16 PT PT05075774T patent/PT1589031E/pt unknown
- 2003-07-16 EP EP05075774A patent/EP1589031B1/en not_active Expired - Lifetime
- 2003-07-16 ES ES03764029.9T patent/ES2544624T3/es not_active Expired - Lifetime
- 2003-07-16 AT AT05075774T patent/ATE370161T1/de active
- 2003-07-16 JP JP2004520912A patent/JP2005532809A/ja active Pending
- 2003-07-16 EP EP03764029.9A patent/EP1521828B1/en not_active Expired - Lifetime
- 2003-07-16 BR BR0312691-9A patent/BR0312691A/pt not_active IP Right Cessation
- 2003-07-16 CN CNB038169169A patent/CN100569944C/zh not_active Expired - Fee Related
- 2003-07-16 EP EP05077470A patent/EP1655372A3/en not_active Withdrawn
- 2003-07-16 WO PCT/GB2003/003230 patent/WO2004007709A2/en not_active Ceased
- 2003-07-16 AU AU2003246965A patent/AU2003246965B2/en not_active Ceased
- 2003-07-16 EP EP08075113A patent/EP1967520A2/en not_active Withdrawn
- 2003-07-16 DK DK05075774T patent/DK1589031T3/da active
- 2003-07-16 CA CA2492153A patent/CA2492153C/en not_active Expired - Fee Related
- 2003-07-16 MX MXPA05000139A patent/MXPA05000139A/es active IP Right Grant
- 2003-07-16 DE DE60315723T patent/DE60315723T2/de not_active Expired - Lifetime
- 2003-07-16 US US10/497,135 patent/US7300942B2/en not_active Expired - Lifetime
- 2003-07-16 EP EP10179385A patent/EP2277898A3/en not_active Withdrawn
- 2003-07-16 ES ES05075774T patent/ES2296063T3/es not_active Expired - Lifetime
-
2005
- 2005-11-08 US US11/269,215 patent/US20060078980A1/en not_active Abandoned
-
2007
- 2007-07-16 US US11/778,264 patent/US7390895B2/en not_active Expired - Lifetime
- 2007-07-16 US US11/778,319 patent/US7645768B2/en not_active Expired - Fee Related
- 2007-10-15 CY CY20071101328T patent/CY1107764T1/el unknown
- 2007-10-31 US US11/931,474 patent/US20080287482A1/en not_active Abandoned
-
2008
- 2008-02-07 JP JP2008028178A patent/JP2008200039A/ja not_active Ceased
- 2008-02-07 JP JP2008028177A patent/JP4751899B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-09 JP JP2009255660A patent/JP2010075187A/ja not_active Withdrawn
-
2011
- 2011-03-11 US US13/046,304 patent/US9040259B2/en not_active Expired - Lifetime
-
2014
- 2014-04-09 JP JP2014080591A patent/JP2014176384A/ja active Pending
-
2015
- 2015-03-02 US US14/635,979 patent/US9605001B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107764T1 (el) | Παραγωγη πολυκετιδιων και αλλων φυσικων προϊοντων | |
| Xu et al. | Recent advances in the applications of promoter engineering for the optimization of metabolite biosynthesis | |
| Davis et al. | Directing evolution: the next revolution in drug discovery? | |
| Pointon et al. | A highly unusual thioester bond in a pilus adhesin is required for efficient host cell interaction | |
| Choi et al. | Enhanced production of recombinant proteins with Corynebacterium glutamicum by deletion of insertion sequences (IS elements) | |
| WO2003066818A3 (en) | Secretion, transcription and sporulation genes in bacillus clausii | |
| ATE361286T1 (de) | Borrelidin-derivate und ihre medizinische anwendung | |
| NO20075088L (no) | Vertscelle omfattende en vektor for fremstilling av proteiner som krever gamma-karboksylering | |
| WO2006136831A3 (en) | Gene expression technique | |
| WO2006012366A3 (en) | Methods for making and using recombinant bacillus thuringiensis spores | |
| Swalley et al. | Screening factors effecting a response in soluble protein expression: formalized approach using design of experiments | |
| Hansmeier et al. | The surface (S)-layer gene cspB of Corynebacterium glutamicum is transcriptionally activated by a LuxR-type regulator and located on a 6 kb genomic island absent from the type strain ATCC 13032 | |
| Zheng et al. | Topology engineering via protein catenane construction to strengthen an industrial biocatalyst | |
| Ravikumar et al. | A chimeric two-component regulatory system-based Escherichia coli biosensor engineered to detect glutamate | |
| Park et al. | Design of 5′-untranslated region variants for tunable expression in Escherichia coli | |
| ATE532861T1 (de) | Expressionsvektor | |
| WO2004024898A3 (en) | Nematode fatty acid desaturase-like sequences | |
| WO2001074863A3 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| Endoh et al. | A highly productive system for cell-free protein synthesis using a lysate of the hyperthermophilic archaeon, Thermococcus kodakaraensis | |
| Rao et al. | Characterization of Mycobacterium tuberculosis ribosome recycling factor (RRF) and a mutant lacking six amino acids from the C-terminal end reveals that the C-terminal residues are important for its occupancy on the ribosome | |
| Finger et al. | Impact of rare codons and the functional coproduction of rate-limiting tRNAs on recombinant protein production in Bacillus megaterium | |
| WO2005093069A3 (en) | Production of mersacidin and its variants in sigh and/or mrsa negative bacillus host cells | |
| EP1321517A3 (en) | Gluconobacter oxydans 2-ketoreductase enzyme and applications thereof | |
| DE60335703D1 (de) | Verbesserte proteinexpression in bacillus subtilis | |
| HUP0101569A2 (hu) | Egy génklaszterből származó gének |